ArticleMolecular & cellular proteomics : MCP2024
Promises and Challenges of populational Proteomics in Health and Disease.
Article in Molecular & cellular proteomics : MCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- From Method-Defined Signals to Reference Measurement Procedures: Two Decades of Mass Spectrometry-Based ProGRP Quantification.Journal of proteome research · 2026Article
- Development and Validation of a Streamlined Workflow for Proteomic Analysis of Proteins and Post-translational Modifications from Dried Blood.Journal of proteome research · 2026Article
- Long-term temporal stability of circulating proteins in older adults.Nature communications · 2026Article
- Associations of 6600 SomaScan proteins with demographic, lifestyle, environmental and health characteristics in Chinese adults.Scientific reports · 2026Article
- Colocalization and discordance between plasma and brain protein quantitative trait loci.bioRxiv : the preprint server for biology · 2026Article
- Plasma Proteins Associated With Psychosocial Factors and Heart Disease: The Jackson Heart Study.Arteriosclerosis, thrombosis, and vascular biology · 2026Article
- Review
- Multiomics Profiling Supports Cathepsin B as a Protective Factor in Cerebral Small Vessel Disease.Research square · 2026Article
- Post-translational Modifications in Proteins: Prediction Methods, Biological Functions, and Diseases.MedComm · 2026Review
- Proteomics signatures associated with cognitive trajectories: evidence from the English Longitudinal Study of Ageing.medRxiv : the preprint server for health sciences · 2026Article
- New opportunities and challenges for nonshedder tumors.Fundamental research · 2026Review
- Spatial protein expression patterns across pathologically-associated fibers revealed molecular specialization in inclusion body myositis.Cell communication and signaling : CCS · 2026Article
- Exploration of immune phenotypes in self-sampling citizens.iScience · 2026Article
- Harnessing New Tools for Old Challenges: Optimising Neat Plasma Proteomics with Automation and Gas-Phase Fractionation.ACS measurement science au · 2026Article
- RACGAP1 defines a malignant proliferative niche and represents a therapeutic vulnerability in lung adenocarcinoma.Translational lung cancer research · 2026Article
- Integration of clinical and proteomic risk factors enhances prognostic modelling of incident vascular complications in type 2 diabetes.Cardiovascular diabetology · 2026Article
- Synergism between Distribution, Mechanistic and Omics Analyses in Studies on Assessing Environmental Exposure and Human Health Impact.Environment & health (Washington, D.C.) · 2026Article
- Olink Proteomics in Heart Failure: A Comprehensive Review of Applications From Biomarker Discovery to Pathophysiological Insights and Clinical Implementation.Reviews in cardiovascular medicine · 2026Review
- Proteomics research in aging: a bibliometric and visualized analysis of evolution and emerging trends (1998-2024 and early 2025).Biogerontology · 2025Article
- A genome-wide association study of mass spectrometry proteomics using a nanoparticle enrichment platform.Nature genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in proteomic assay technologies have significantly increased coverage and throughput, enabling recent increases in the number of large-scale population-based proteomic studies of human plasma and serum. Improvements in multiplexed protein assays have facilitated the quantification of thousands of proteins over a large dynamic range, a key requirement for detecting the lowest-ranging, and potentially the most disease-relevant, blood-circulating proteins. In this perspective, we examine how populational proteomic datasets in conjunction with other concurrent omic measures can be leveraged to better understand the genomic and non-genomic correlates of the soluble proteome, constructing biomarker panels for disease prediction, among others. Mass spectrometry workflows are discussed as they are becoming increasingly competitive with affinity-based array platforms in terms of speed, cost, and proteome coverage due to advances in both instrumentation and workflows. Despite much success, there remain considerable challenges such as orthogonal validation and absolute quantification. We also highlight emergent challenges associated with study design, analytical considerations, and data integration as population-scale studies are run in batches and may involve longitudinal samples collated over many years. Lastly, we take a look at the future of what the nascent next-generation proteomic technologies might provide to the analysis of large sets of blood samples, as well as the difficulties in designing large-scale studies that will likely require participation from multiple and complex funding sources and where data sharing, study designs, and financing must be solved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.